Professor at UT MD Anderson cancer center, United States
👨🔬 Dr. Pramod N. Nehete, PhD, is a distinguished Professor at the Michale E. Keeling Center for Comparative Medicine and Research, UT MD Anderson Cancer Center. 🎓 With a Ph.D. in Biochemistry and extensive experience in comparative medicine, his expertise spans immunology, HIV research, and vaccine development. 🧪 Dr. Nehete is renowned for his pioneering work on nanochannel drug delivery systems for HIV treatment in non-human primates. 🌟 His accolades include prestigious fellowships and memberships in esteemed scientific societies. 🏅 Dr. Nehete’s commitment to advancing medical science is evident through his editorial roles and grant review activities. His research interests encompass immunotherapy, infectious diseases, and translational medicine. 🧬
Profile
Scopus
🎓 Education
Dr. Nehete holds a Ph.D. in Biochemistry from the University of Poona, India, along with an M.S. in Biochemistry and a B.S. in Biology/Chemistry from esteemed Indian universities. 📚 His academic journey laid the foundation for his illustrious career in biomedical research. 🧬
👨💼 Experience
With over two decades of service at UT MD Anderson Cancer Center, Dr. Nehete has contributed significantly to comparative medicine and translational molecular pathology. 🏥 He has led numerous research projects, focusing on HIV treatment and vaccine development, demonstrating his expertise in GLP studies and flow cytometry. 💉
🔬 Research Interests
Dr. Nehete’s research interests revolve around immunotherapy, infectious diseases, and vaccine development. 🦠 He is particularly passionate about leveraging animal models to study HIV/AIDS and emerging infectious diseases like Zika virus. 🐒
🏅 Awards
Dr. Nehete has received prestigious fellowships and scholarships, recognizing his outstanding contributions to biomedical research. 🌟 His dedication to scientific excellence has earned him recognition from the Government of India and the Center for Scientific and Industrial Research. 🏆
Publications Top Notes
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates” (2023)
“Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates” (2023)
“Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats” (2022)
“Extending Drug Release from Implants via Transcutaneous Refilling with Solid Therapeutics” (2022)
“Ultra-long acting prodrug of dolutegravir and delivery system – Physicochemical, pharmacokinetic and formulation characterizations” (2021)
“Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer’s disease pathology in aged squirrel monkeys” (2021)
“Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV-Challenged Nonhuman Primates” (2021)